GLP-1 receptor agonist drugs — including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Saxenda, and Victoza — are increasingly linked to reports of severe gastrointestinal motility disorders. These conditions involve abnormal or impaired movement of the digestive tract and can lead to digestive paralysis, bowel shutdown, hospitalization, and long-term disability.
Motility disorders are now recognized as a core injury category in GLP-1 litigation, encompassing gastroparesis, intestinal obstruction, ileus, and chronic bowel dysfunction.
This page explains what motility disorders are, how GLP-1 drugs may contribute, symptoms to watch for, and when legal action may be appropriate.
What Are Gastrointestinal Motility Disorders?
A motility disorder occurs when the muscles or nerves of the digestive tract do not move food properly through the system.
Commonly referred to as dysmotility, these disorders are distinct from structural blockages, as the issue is functional
Normal digestion relies on coordinated muscular contractions (peristalsis). When these signals are disrupted, food may:
- move too slowly
- stop moving entirely
- back up in the stomach or intestines
Motility disorders can affect:
- the stomach
- the small intestine
- the large intestine (colon)
- or multiple sections simultaneously
Common Motility Disorders Reported With GLP-1 Drugs
Gastroparesis (Stomach Paralysis)
- delayed stomach emptying
- chronic nausea and vomiting
- early satiety
- inability to tolerate solid food
➡️ Related page: Gastroparesis
Intestinal Obstruction / Ileus / bowel obstruction (blockage)
- bowel shutdown without physical blockage
- severe abdominal pain and distension
- constipation lasting days or weeks
- vomiting and inability to pass gas
➡️ Related page: Intestinal Obstruction
Ileus is considered a functional yet non-mechanical disruption of intestinal motility. The bowel ceases transporting food, gas and fluids. Ileus usually results from stomach surgery or in some cases can be linked to drugs such as opioids or GLP-1 medications. In some cases, Ileus is the result of infection, or even perhaps imbalances that are metabolic. Symptom of Ileus include but are not limited to serious stomach bloating, nausea, pain, constipation and vomiting. Medical care generally relies on resting the bowel, fluids taken intravenously, and resolving the underlying medical problem. In unusual cases a nasogastric (NG) tube can be utilized in order to decompress the abdomen.
Chronic Constipation & Colonic Inertia
- extreme constipation unresponsive to treatment
- infrequent bowel movements
- bloating and abdominal pain
- dependence on laxatives or enemas
Generalized GI Dysmotility
Some patients experience multi-level digestive paralysis, involving both stomach and intestines, resulting in:
- inability to eat normally
- repeated dehydration
- malnutrition
- frequent hospital visits
How GLP-1 Drugs Affect Digestive Motility
GLP-1 drugs are designed to slow digestion as part of their mechanism of action.
They work by:
- delaying gastric emptying
- suppressing appetite
- slowing intestinal movement
- altering gut–brain signaling
While this effect can aid blood sugar control and weight loss, in some patients it appears to become pathological, leading to excessive or prolonged digestive slowing.
Why Motility Disorders Can Become Severe or Permanent
In reported cases, motility disorders may:
- worsen with dose increases
- persist after stopping the drug
- fail to resolve with standard treatment
- progress from mild symptoms to full paralysis
Some patients report symptoms lasting months or years, even after discontinuation.
Symptoms That May Indicate a Serious Motility Disorder
Seek medical attention if you experience:
- persistent nausea or vomiting
- inability to tolerate food or fluids
- severe bloating or abdominal distension
- constipation lasting more than several days
- abdominal pain with no bowel movement
- repeated dehydration
- frequent ER visits for GI symptoms
These symptoms may indicate functional bowel shutdown, not temporary side effects.
Diagnosis of Motility Disorders
Diagnosis often involves:
- gastric emptying studies
- abdominal CT or MRI
- X-rays showing bowel dilation
- exclusion of mechanical blockage
- GI specialist evaluation
- motility testing
Objective testing is often critical in both medical treatment and legal claims.
Motility Disorders as a Legal Injury Category
Motility disorders are legally significant because they often involve:
- hospitalization
- invasive testing
- feeding restrictions or liquid diets
- long-term disability
- inability to work
- reduced quality of life
They are frequently cited in GLP-1 lawsuits as evidence of:
- severe adverse drug reactions
- inadequate risk warnings
- under-disclosed long-term effects
Evidence Used in Motility Disorder Lawsuits
Strong claims often include:
- GI specialist records
- gastric emptying test results
- imaging showing bowel dilation or stasis
- ER and hospital admission notes
- IV hydration or nutrition support
- documented symptom persistence
- GLP-1 prescription history
➡️ Evidence guide: Medical Records
Who May Qualify for a Motility Disorder Claim Review
You may qualify if:
- you used a GLP-1 drug, AND
- you developed severe digestive symptoms, AND
- you were diagnosed with a motility disorder, gastroparesis, ileus, or obstruction, AND/OR
- you required hospitalization or long-term care
➡️ Start here: File a Claim
Relationship to Other GLP-1 Injury Claims
Motility disorders often overlap with:
Severe gastrointestinal motility disorders represent one of the most serious and disabling categories of GLP-1 drug injuries. While GLP-1 medications intentionally slow digestion, in some patients this effect appears to escalate into digestive paralysis, bowel shutdown, and long-term impairment.
If you experienced severe or persistent digestive dysfunction after using a GLP-1 drug, you may qualify for a legal claim review.
➡️ Start your review: File a Claim